Serum albumin levels and serum albumin-globulin ratio are associated with poor prognosis in glioblastoma.

Abstract

BackgroundSerum albumin levels (ALB) and albumin-globulin ratio (AGR) are reliable and convenient markers of the nutritional status and inflammation of human body, and ALB has been identified as a prognostic factor in the patients of glioblastoma (GBM). However, no literature has reported the prediction value of AGR for GBM.MethodsIn this study we evaluate the serum ALB and AGR levels for GBM. A total of 126 patients with GBM who underwent surgical resection in our institution between 2013 and 2017 were analyzed retrospectively. Clinical information was obtained from electronic medical records. Multiple logistic regression and Cox proportional hazards models were used to assess the prediction value of preoperative ALB and AGR for GBM.ResultsPreoperative ALB (HR 0.342, 95% CI, 0.123–0.954, P=0.040) and postoperative adjuvant therapy (HR 0.042, 95% CI, 0.005–0.330, P=0.003) were significantly related to progression-free survival (PFS). Cox regression analysis showed the significance of adjuvant therapy (HR 3.579, 95% CI, 2.236–5.729, P<0.001). Preoperative AGR (HR 0.280, 95% CI, 0.103–0.763, P=0.013) and adjuvant therapy (HR 0.156, 95% CI, 0.047–0.513, P=0.002) were showed significance, and Cox regression analysis showed preoperative AGR (HR 1.810, 95% CI, 1.095–2.992, P=0.021) and adjuvant therapy (HR 4.702, 95% CI, 2.841–7.782, P<0.001) were independent predictors of overall survival (OS).ConclusionsThe ALB and AGR had significant predictive values for the prognosis of GBM; postoperative adjuvant treatment is also an independent predictor for the prognosis of GBM patients.